At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
In Brief
A Phase 2 clinical trial evaluating Biospecimen Collection, Bone Marrow Biopsy, and 3 other interventions for Acute Myeloid Leukemia. Active but no longer recruiting, targeting 82 participants across 46 sites in 2 countries.
Detailed Summary
This phase II trial studies how well nivolumab works in eliminating any remaining cancer cells and preventing cancer from returning in patients with acute myeloid leukemia that had a decrease in or disappearance of signs and symptoms of cancer after receiving chemotherapy. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Study Details
Timeline
Interventions
Undergo collection of blood samples
Undergo bone marrow biopsy
Undergo standard of care clinical observation
Undergo ECHO
Given IV